Neoadjuvant randomized trial of degarelix (Deg) +/- cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).


Antonarakis E. S. , Zahurak M., Schaeffer E. M. , Partin A. W. , Ross A., Allaf M., ...More

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35 identifier